MUC16 and breast cancer: Figure 9D shows that both high-TMB and low-risk patients may benefit more from immunotherapy. Furthermore, we examined differences in the distribution of detected somatic mutation signatures between high-risk and low-risk groups in the TCGA-BC dataset. The mutation rates of TP53, TTN, KMT2D, MUC16, ARID1A and KDM6A genes in both groups of BC patients were higher than 20% (Figures 9E, F).